Shanghai Pharmaceuticals Holding Co., Ltd

SHSE:601607 Stock Report

Market Cap: CN¥68.6b

Shanghai Pharmaceuticals Holding Valuation

Is 601607 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 601607 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 601607 (CN¥20.91) is trading above our estimate of fair value (CN¥16.2)

Significantly Below Fair Value: 601607 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 601607?

Key metric: As 601607 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 601607. This is calculated by dividing 601607's market cap by their current earnings.
What is 601607's PE Ratio?
PE Ratio19.2x
EarningsCN¥4.03b
Market CapCN¥68.56b

Price to Earnings Ratio vs Peers

How does 601607's PE Ratio compare to its peers?

The above table shows the PE ratio for 601607 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average16.1x
000963 Huadong Medicine
19.2x13.2%CN¥61.7b
600998 Jointown Pharmaceutical Group
12.9x17.1%CN¥26.4b
600511 China National Medicines
12x9.1%CN¥25.9b
600056 China Meheco Group
20.4xn/aCN¥18.4b
601607 Shanghai Pharmaceuticals Holding
19.2x18.5%CN¥69.2b

Price-To-Earnings vs Peers: 601607 is expensive based on its Price-To-Earnings Ratio (19.2x) compared to the peer average (16.1x).

Price to Earnings Ratio vs Industry

How does 601607's PE Ratio compare vs other companies in the CN Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
601607 19.2xIndustry Avg. 33.4xNo. of Companies5PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 601607 is good value based on its Price-To-Earnings Ratio (19.2x) compared to the CN Healthcare industry average (33.4x).

Price to Earnings Ratio vs Fair Ratio

What is 601607's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

601607 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio19.2x
Fair PE Ratio27.2x

Price-To-Earnings vs Fair Ratio: 601607 is good value based on its Price-To-Earnings Ratio (19.2x) compared to the estimated Fair Price-To-Earnings Ratio (27.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 601607 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥20.91
CN¥21.51
+2.9%
14.8%CN¥24.90CN¥13.60n/a8
Nov ’25CN¥19.54
CN¥21.51
+10.1%
14.8%CN¥24.90CN¥13.60n/a8
Oct ’25CN¥21.15
CN¥21.42
+1.3%
17.0%CN¥24.90CN¥12.20n/a8
Sep ’25CN¥18.60
CN¥21.34
+14.8%
17.0%CN¥24.90CN¥12.20n/a8
Aug ’25CN¥19.37
CN¥20.83
+7.5%
17.2%CN¥24.90CN¥12.40n/a8
Jul ’25CN¥19.38
CN¥20.67
+6.6%
16.9%CN¥24.90CN¥12.40n/a8
Jun ’25CN¥18.16
CN¥20.78
+14.4%
18.2%CN¥26.40CN¥12.40n/a8
May ’25CN¥17.92
CN¥20.78
+16.0%
18.2%CN¥26.40CN¥12.40n/a8
Apr ’25CN¥17.62
CN¥21.14
+20.0%
18.5%CN¥26.80CN¥12.40n/a8
Mar ’25CN¥18.21
CN¥21.60
+18.6%
17.6%CN¥26.80CN¥13.00n/a8
Feb ’25CN¥16.82
CN¥20.67
+22.9%
16.0%CN¥23.63CN¥13.00n/a8
Jan ’25CN¥16.73
CN¥21.17
+26.6%
10.5%CN¥23.63CN¥17.00n/a8
Dec ’24CN¥17.94
CN¥21.31
+18.8%
10.1%CN¥23.63CN¥17.00n/a8
Nov ’24CN¥18.05
CN¥21.31
+18.1%
10.1%CN¥23.63CN¥17.00CN¥19.548
Oct ’24CN¥18.08
CN¥20.73
+14.6%
11.9%CN¥23.63CN¥17.00CN¥21.158
Sep ’24CN¥17.84
CN¥23.51
+31.8%
19.0%CN¥29.21CN¥17.00CN¥18.608
Aug ’24CN¥20.10
CN¥24.76
+23.2%
17.2%CN¥29.21CN¥17.00CN¥19.3710
Jul ’24CN¥22.41
CN¥24.31
+8.5%
17.1%CN¥29.21CN¥17.00CN¥19.3810
Jun ’24CN¥22.84
CN¥24.31
+6.4%
17.1%CN¥29.21CN¥17.00CN¥18.1610
May ’24CN¥22.91
CN¥24.31
+6.1%
17.1%CN¥29.21CN¥17.00CN¥17.9210
Apr ’24CN¥20.37
CN¥22.20
+9.0%
19.5%CN¥27.00CN¥14.51CN¥17.628
Mar ’24CN¥19.76
CN¥22.20
+12.3%
19.5%CN¥27.00CN¥14.51CN¥18.218
Feb ’24CN¥19.05
CN¥22.20
+16.5%
19.5%CN¥27.00CN¥14.51CN¥16.828
Jan ’24CN¥17.83
CN¥21.03
+17.9%
18.8%CN¥25.20CN¥14.51CN¥16.737
Dec ’23CN¥19.20
CN¥21.03
+9.5%
18.8%CN¥25.20CN¥14.51CN¥17.947
Nov ’23CN¥17.90
CN¥20.95
+17.0%
19.1%CN¥25.20CN¥14.51CN¥18.057

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Shenzhen Lifotronic Technology

CN¥7.0b

Research, develops, manufactures, and markets medical devices for diagnostics, clinical medicine, skin, and human health related purposes in China.

688389

CN¥16.65

7D

-4.6%

1Y

-27.1%

Winner Medical

CN¥19.4b

Engages in the research and development, manufacture, and marketing of cotton-based medical dressings and medical disposables, and consumer products in China.

300888

CN¥33.40

7D

0.4%

1Y

-16.2%

Innovita Biological Technology

CN¥5.6b

Engages in the research and development, manufacturing, marketing, and sales of POCT rapid diagnostic products.

688253

CN¥40.80

7D

-8.7%

1Y

59.1%